drugset
drugset / Trial / NCT05109663

A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects

NCT05109663 ↗

Phase 1 Completed 26 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.

Timeline

Start
2021-04-14
Primary completion
2021-06-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject RUSERONTINIB Small molecule 50 mg Oral
Subject RUSERONTINIB Small molecule 100 mg Oral
Subject RUSERONTINIB Small molecule 150 mg Oral

Indications

No indication recorded.